According to the SURMOUNT-1 clinical trial, patients using tirzepatide at the highest dose (15 mg weekly) experienced up to 22.5% total body weight loss over 72 weeksgreater than what is typically seen with semaglutide GLP-1
NAD replenishment through intravenous (IV) therapy has emerged as a promising approach to counteract these effects.By directly increasing NAD levels in the bloodstream, IV therapy can enhance mitochondrial function, promote efficient energy metabolism, and activate sirtuins
They do not forecast how you will respond to any specific drug, but they do describe the biology a clinician is prescribing into
Ensure the skin around your eyes is clean and slightly damp
If weight loss is progressing well at 8mg with manageable side effects, there may be no need to escalate further
Jank M, Luhov L, Petivalsk M (2019) On the origin and fate of reactive oxygen species in plant cell compartments